Blue Trust Inc. increased its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 36.3% during the ...
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $80.00 price target on Beam Therapeutics Inc ...
Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON ...
Cantor Fitzgerald upgraded shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) from a neutral rating to an overweight rating in a research note published on Wednesday morning, Marketbeat reports.
Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will encore data from the BEACON Phase 1/2 clinical trial of BEAM- ...
Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...
These factors contribute to the Buy rating as Beam Therapeutics continues to lead innovation in its field. In another report released on January 7, Bernstein also upgraded the stock to a Buy with ...
Check the time stamp on this data. Updated AI-Generated Signals for Beam Therapeutics Inc. (BEAM) available here: BEAM. Type ...
What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and ...